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Abstract — Genetic gluten intolerance is a multifactorial condition characterized by the intestinal synthesis of 
antitransglutaminase antibodies (anti-tTG) which might represent an early stage of this intolerance in absence 
of both intestinal damage and serum anti-tTG.  The double immunofluorescence staining (IF) is able to point 
out these anti-tTG antibodies directly on intestinal biopsy. Her we describe a prospective study in which 
patients were analysed for genetic predisposition (HLA DQ2-DQ8) and serum anti-tTG and were monitored 
for clinical conditions and serum anti-tTG concentration during gluten free diet (GFD) or gluten containing diet 
(GCD). Our results demonstrate that the measurement of intestinal anti-tTG is a useful screening procedure to 
identify patients with genetic predisposition not fullfilling the current diagnostic criteria.
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_____________________________________________________________________ 
1 BACKGROUND
The current diagnostic criteria for genetic gluten intolerance require intestinal mucosal villous atrophy 
and the presence of serum anti-tissue transglutaminase (anti-tTG) antibodies. Anti-tTG antibodies are 
synthesised by specific B lymphocites in the small bowel mucosa at an early stage of gluten intolerance 
even in absence of both intestinal damage and serum anti-tTG.
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2 OBJECTIVES
Our objectives are:
to evaluate by double immunolfuorescence staining (IF) the intestinal anti-tTG in patients undergoing 
to gastrointestinal endoscopy
to correlate IF results with clinical, serological, histological and genetic markers
3 APPROACH & METHODS
General approach
This is a prospective study. Patients were analysed for clinical (anaemia,diarrhea, abdomianl pain), 
genetic (HLA DQ2/8), serological (serum anti-tTG), histological (villous atrophy) and intestinal 
markers. Intestinal markers are intestinal antitransglutaminase antibodies searched with double 
immunofluorescence staining. Patients were monitored for clinical conditions, serum anti-tTG 
concentrations during gluten free diet (GFD) or gluten containing diet (GCD).
Methods
The double immunofluorescence staining technology is applied on intestinal crio-sections in order to 
point out the IgA antibodies against tissue trasnglutaminase (tTG) by using labelled antibodies. IgA are 
labelled with fluorescein (green fluorescent signal) and tTG with rhodamine (red fluorescent signal). 
Through the fluorescent microscope examination, two pictures are taken from the same section: one 
representing IgA distribution (figures A1 and A2) and the other one tTG distribution (figures B1 and 
B2). The overlap of these images, by using an appropriate software, results in a third picture where the 
IgA against tTG are pointed out with a yellow signal obtained from the localization of green IgA signal 
and red tTG signal at the same area (figure C1). If IgA against tTG are not synthesised, no yellow signal 
is raised (figure C2).
4 RESULTS
Intestinal anti-tTG identified 24/708 (3%) and 28/708 (3.5%) subjects with normal mucosa and 
with positive and negative serologic markers, respectively. Half of them (18/24 and 16/28) clinically 
improved in GFD.
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5 POTENTIAL NEW PRODUCTS & SERVICES
Since these autoantibodies are produced at the intestinal level at an early stage, when they are not 
serologically detectable and the small intestinal mucosa is morphologically normal, this approach 
could be very useful for early diagnosis. This technology is already a service described on the IRCCS 
Burlo Garofolo website as a new test to make diagnosis of genetic gluten intolerance at an early stage. 
University Medical Center Maribor already benefits from this service.
6 CURRENT COLLABORATIONS
6.1 With other researchers 
Morena Silvestrini, Ca’Foscari Venice (PP7, Trans2Care)
6.2 With hospitals
University Medical Center Maribor
7 CONTACT OR COLLABORATIONS NEEDED
Our results indicate that the double immunofluorescence staining, identifying intestinal anti-tTG 
antibodies, is able to discover new clinical conditions of genetic gluten intolerance. In order to extend 
the application of this technology in diagnostic field, it’s necessary to start collaborations with many 
other clinical units (as done with University Medical Center Maribor) and companies interested in 
translational research.
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8 COMMUNICATION TOOLS
• Radiol Oncol. 2013 May 21;47(2):128-37
• Curr Pharm Des. 2012;18(35):5753-8
• FASEB J. 2011 Jan;25(1):144-58
9 FUNDS NEEDED
9.1  For applied research (solutions for real-world problems): 25.000 €
9.2  For pilot & demonstrator activities (to develop a prototype): 30.000 €
10 CONCLUSION
The measurement of intestinal anti-tTG is a useful screening procedure to identify patients with genetic 
predisposition (HLA DQ2/8) not fullfilling the current diagnostic criteria that promptly respond to GFD.
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